PTPN22 and breast carcinoma: As p32 protein is over‐expressed on breast cancer cells (surface and intracellular) as well as tumor‐associated lymphocytes and tissues, the authors modified the Lyp‐1 ligand on the nanoparticle surface to specifically target p32 protein.